Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Condyline
2. Condylox
3. Cph86
4. Epipodophyllotoxin
5. Podocon-25
6. Podofilm
7. Podophyllotoxin
8. Podophyllotoxin, (5r-(5 Alpha,5a Alpha,8a Alpha,9 Alpha))-isomer
9. Podophyllotoxin, (5r-(5 Alpha,5a Alpha,8a Alpha,9 Beta))-isomer
10. Podophyllotoxin, (5r-(5 Alpha,5a Alpha,8a Beta,9 Alpha))-isomer
11. Podophyllotoxin, (5r-(5 Alpha,5a Beta,8a Alpha,9 Beta))-isomer
12. Wartec
13. Warticon
1. Podophyllotoxin
2. 518-28-5
3. Condylox
4. Condyline
5. (-)-podophyllotoxin
6. Wartec
7. Podophyllinic Acid Lactone
8. Podophyllotoxin 7
9. Warticon
10. Podofilox [usan]
11. Podophyllum
12. Nsc24818
13. Chembl61
14. Mfcd00075290
15. Nsc-24818
16. (10r,11r,15r,16r)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one
17. (5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
18. Mls000069495
19. (5r,5ar,8ar,9r)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
20. Chebi:50305
21. Podofilox (usan)
22. L36h50f353
23. (5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one
24. Ncgc00022001-05
25. Podofilm
26. Smr000059121
27. Nsc 24818
28. Dsstox_cid_25645
29. Dsstox_rid_81023
30. Dsstox_gsid_45645
31. (5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[5,6-f][1,3]benzodioxol-8-one
32. (5r,5ar,8ar,9r)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8h)-one
33. Podocon-25
34. Podophilox
35. (5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one
36. Ccris 565
37. Hsdb 7238
38. Sr-05000001749
39. Mls002702981
40. Einecs 208-250-4
41. Podofillina
42. Podophylotoxin
43. Ai3-50456
44. Mayapple Isolate
45. Unii-l36h50f353
46. Condylox (tn)
47. Cas-518-28-5
48. Podophyllotoxin,(s)
49. Prestwick_1018
50. Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5alpha,5abeta,8aalpha,9alpha))-
51. Podofillina [italian]
52. Podophyllotoxin (ban)
53. Podophyllotoxin, 95%
54. Spectrum_000199
55. Podofilox [hsdb]
56. Opera_id_1397
57. Prestwick0_000782
58. Prestwick1_000782
59. Prestwick2_000782
60. Prestwick3_000782
61. Spectrum2_000878
62. Spectrum4_000592
63. Spectrum5_001368
64. Podofilox [vandf]
65. Upcmld-dp035
66. Podophyllotoxin [mi]
67. Schembl42243
68. Bspbio_000884
69. Bspbio_002352
70. Kbiogr_001084
71. Kbioss_000679
72. Mls001148204
73. Mls002172467
74. Mls006010754
75. Mls006011412
76. Bidd:gt0123
77. Divk1c_000292
78. Unii-16902yvy2b
79. Spbio_000955
80. Spbio_002823
81. Bpbio1_000974
82. Ccris 4391
83. Podofilox [orange Book]
84. Podophyllotoxin [mart.]
85. Dtxsid3045645
86. Podophyllotoxin [who-dd]
87. Upcmld-dp035:001
88. Upcmld-dp035:002
89. Bcbcmap01_000165
90. Hms500o14
91. Kbio1_000292
92. Kbio2_000679
93. Kbio2_003247
94. Kbio2_005815
95. Amy2648
96. Ninds_000292
97. 16902yvy2b
98. Hms1570m06
99. Hms2093p16
100. Hms2097m06
101. Hms2235a23
102. Hms3259j19
103. Hms3714m06
104. Pharmakon1600-02300332
105. (5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-furo(3',4':6,7)naphtho[2,3-d]-1,3-dioxol-6(5ah)-one
106. 9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
107. Albb-020906
108. Bcp24085
109. Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.))-
110. Podophyllotoxin, Analytical Standard
111. Zinc3861806
112. Einecs 232-546-2
113. Tox21_110874
114. Tox21_202922
115. B18-5c
116. Bbl033695
117. Bdbm50035218
118. Ccg-39894
119. Nsc759591
120. Stk801918
121. Podophyllotoxin [ep Monograph]
122. Akos000265559
123. Tox21_110874_1
124. Ac-1656
125. Cs-1185
126. Db01179
127. Ks-1281
128. Nc00675
129. Nd-1185
130. Nsc-759591
131. Sdccgmls-0066888.p001
132. Idi1_000292
133. Smp1_000243
134. Ncgc00022001-03
135. Ncgc00022001-07
136. Ncgc00022001-08
137. Ncgc00022001-09
138. Ncgc00022001-10
139. Ncgc00022001-11
140. Ncgc00022001-13
141. Ncgc00022001-14
142. Ncgc00260468-01
143. (5r,9r,5ar,8ar)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,9,5a,8a-pentahydro-2h -isobenzofurano[5',6'-2,1]benzo[4,5-d]1,3-dioxolan-6-one
144. 1,3,3a,4,9,9a-hexahydro-9-hydroxy-6,7-(methylenedioxy)-4-(3',4',5'-trimethoxyphenyl)benz(f)isobenzofuran-3-one
145. Hy-15552
146. Nci60_001981
147. Rd4-6269
148. P1771
149. En300-52746
150. D05529
151. P-6980
152. 518p285
153. A828801
154. Q421193
155. Sr-01000003030
156. Sr-01000003030-3
157. Sr-05000001749-1
158. Sr-05000001749-2
159. Brd-k47869605-001-05-6
160. Brd-k47869605-001-18-9
161. Z1258578359
162. (10r,11r,15r,16r)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0?,?.0??,??]hexadeca-1(9),2,7-trien-12-one
163. (10r,11r,15r,16r)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.03,7.011,15]hexadeca-1,3(7),8-trien-12-one
164. (5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[6,5-f][1,3]benzodioxol-8-one
165. (5r,5ar,8ar,9r)-5-oxidanyl-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
166. 11016-28-7
167. 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, [5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]
168. Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5r,5ar,8ar,9r)-
169. Furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, [5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]-
170. Naphtho[2,3-dioxole-6-carboxylic Acid, 5,6,7,8-tetrahydro-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl-, .gamma.-lactone
| Molecular Weight | 414.4 g/mol |
|---|---|
| Molecular Formula | C22H22O8 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 414.13146766 g/mol |
| Monoisotopic Mass | 414.13146766 g/mol |
| Topological Polar Surface Area | 92.7 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Condylox |
| PubMed Health | Podofilox (On the skin) |
| Drug Classes | Keratolytic |
| Drug Label | Condylox is the brand name of podofilox, an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Condylox 0.5% Solution is formulated for top... |
| Active Ingredient | Podofilox |
| Dosage Form | Gel; Solution |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Watson Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Podofilox |
| Drug Label | Podofilox Topical Solution 0.5% is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox Topical Solution 0.5% is formulated for... |
| Active Ingredient | Podofilox |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Precision Dermat; Paddock |
| 3 of 4 | |
|---|---|
| Drug Name | Condylox |
| PubMed Health | Podofilox (On the skin) |
| Drug Classes | Keratolytic |
| Drug Label | Condylox is the brand name of podofilox, an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Condylox 0.5% Solution is formulated for top... |
| Active Ingredient | Podofilox |
| Dosage Form | Gel; Solution |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Watson Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Podofilox |
| Drug Label | Podofilox Topical Solution 0.5% is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox Topical Solution 0.5% is formulated for... |
| Active Ingredient | Podofilox |
| Dosage Form | Solution |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Precision Dermat; Paddock |
Antiviral (topical)
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1355
Podofilox is indicated for the treatment of condyloma acuminatum of the external genital areas; the gel, but not the solution, may be used for perianal warts. Neither the gel nor the solution should be used to treat warts on mucous membranes, including membranous areas of the urethra, rectum, and vagina. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2337
Because of the potential for adverse local reactions, the recommended dose, frequency of application, and duration of treatment of topical podofilox should not be exceeded. There is no evidence that applying podofilox more frequently than recommended would increase efficacy; however, more frequent application would be expected to increase the risk of local adverse reactions and increase systemic absorption of the drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3455
Pregnancy risk category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2337
Podofilox generally is well tolerated when applied topically. In clinical studies evaluating topical podofilox in otherwise healthy adults 18 years of age or older with external genital and/or perianal warts caused by human papillomavirus, up to 6% of patients discontinued the drug because of adverse local reactions; however, serious systemic effects have not been reported to date.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3455
Adverse local reactions, including burning, pain, inflammation, erosion, and pruritus, commonly occur at the site of application of podofilox 0.5% gel or 0.5% solution. These reactions usually are mild to moderate in severity; however, severe local reactions have been reported, especially during the first 2 weeks of therapy. Adverse local reactions generally resolve within 4 weeks following completion of topical podofilox therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3455
For more Drug Warnings (Complete) data for PODOFILOX (9 total), please visit the HSDB record page.
For treatment of external genital warts (Condyloma acuminatum).
Podofilox, also called podophyllotoxin, is a purer and more stable form of podophyllin in which only the biologically active portion of the compound is present. Podofilox is used to remove certain types of warts on the outside skin of the genital areas.
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Keratolytic Agents
Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. (See all compounds classified as Keratolytic Agents.)
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06B - Chemotherapeutics for topical use
D06BB - Antivirals
D06BB04 - Podophyllotoxin
Absorption
Topical application of 0.05 mL of 0.5% podofilox solution to external genitalia did not result in detectable serum levels. Applications of 0.1 to 1.5 mL resulted in peak serum levels of 1 to 17 ng/mL one to two hours after application.
Small amounts of podofilox may be absorbed systemically following topical application. In a study in adults with anogenital warts caused by human papillomavirus, topical application of 0.05 mL of podofilox 0.5% solution to external genitalia did not result in detectable serum concentrations of the drug; however, topical application of 0.1-1.5mL of the solution resulted in peak serum concentrations of 1-17 ng/mL at 1-2 hours after application.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3456
1.0 to 4.5 hours.
The serum elimination half-life of podofilox is estimated to range from 1-4.5 hours.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 3456
The exact mechanism of action is not well understood. It does appear, however, that it and its derivatives may bind and inhibit topoisomerase II during the late S and early G2 stage. The drug may bind and stabilize the temporary break caused by the enzyme. This disrupts the reparation of the break through which the double-stranded DNA passes, and consequently stops DNA unwinding and replication
The exact mechanism of action for podofilox is unknown. Podofilox is a potent mitotoxic agent that inhibits cell mitosis; cell division stops, other cellular processes are impaired, necrosis occurs, and the affected tissues gradually erode.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2337
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;TOPICAL - 0.5%
USFDA APPLICATION NUMBER - 19795
DOSAGE - GEL;TOPICAL - 0.5%
USFDA APPLICATION NUMBER - 20529
Related Excipient Companies
Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Film Formers & Plasticizers
Coating Systems & Additives
Topical
Controlled & Modified Release
Digital Content
DATA COMPILATION #PharmaFlow
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
